A Phase 3, Multicenter, Open-Label, 12-Month Extension Safety and Tolerability Trial of Lisdexamfetamine Dimesylate in Adults With Binge Eating Disorder
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Background: A 12-month, open-label extension study assessed the long-term safety and tolerability of lisdexamfetamine dimesylate (LDX) in adults with binge eating disorder (BED). Methods: Adults (aged 18–55 y) with BED who completed 1 of 3 antecedent studies were enrolled in a 52-week, open-label extension study (dose optimization, 4 weeks [initial titration dose, 30-mg LDX; target doses, 50- or 70-mg LDX]; dose maintenance, 48 weeks). Safety evaluations included the occurrence of treatment-emergent adverse events (TEAEs), vital sign and weight assessments, and Columbia-Suicide Severity Rating Scale responses. Results: Of the 604 enrolled participants, 599 (521 women and 78 men) comprised the safety analysis set, and 369 completed the study. Mean (SD) LDX exposure was 284.3 (118.84) days; cumulative LDX exposure duration was 12 months or longer in 344 participants (57.4%). A total of 506 participants (84.5%) reported TEAEs (TEAEs leading to treatment discontinuation, 54 [9.0%]; severe TEAEs, 42 [7.0%]; serious TEAEs, 17 [2.8%]). Treatment-emergent adverse events reported in greater than or equal to 10% of participants were dry mouth (27.2%), headache (13.2%), insomnia (12.4%), and upper respiratory tract infection (11.4%). Mean (SD) changes from antecedent study baseline in systolic and diastolic blood pressure, pulse, and weight at week 52/early termination (n = 597) were 2.19 (11.043) and 1.77 (7.848) mm Hg, 6.58 (10.572) beats per minute, and −7.04 (7.534) kg, respectively. On the Columbia-Suicide Severity Rating Scale, there were 2 positive responses for any active suicidal ideations; there were no positive responses for suicidal behavior or completed suicides. Conclusions: In this 12-month, open-label, extension study, the long-term safety and tolerability of LDX in adults with BED were generally consistent with its established profile for attention-deficit/hyperactivity disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Posner, K., Brown, G. K., Stanley, B., Brent, D. A., Yershova, K. V., Oquendo, M. A., Currier, G. W., Melvin, G. A., Greenhill, L., Shen, S., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10111704 · Cited by 5,157
McElroy, S. L., Hudson, J. I., Mitchell, J. E., Wilfley, D., Ferreira-Cornwell, M. C., Gao, J., Wang, J., Whitaker, T., Jonas, J., & Gasior, M. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.2162 · Cited by 322 · cited 9×
“Overall, there are limited data on the long-term effects of pharmacotherapy for BED.”
BackgroundMethodResultInfluentialSelf-citationMcElroy, S. L., Hudson, J., Ferreira-Cornwell, M. C., Radewonuk, J., Whitaker, T., & Gasior, M. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2015.275 · Cited by 254 · cited 14×
“Anxiety and palpitations were also reported by more than 2% of study participants in the short-term studies.1,4 The increases from baseline in SBP and pulse observed in this study are also consistent with observations from the short-term studies of LDX1,4; DBPwas increased in this study and in the pivotal phase 3 stud…”
BackgroundMethodResultInfluentialSelf-citationAbsorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine
Pennick (2010) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s9749 · Cited by 170 · cited 1×
“Lisdexamfetamine dimesylate is absorbed by the gastrointestinal tract and subsequently metabolized to its active form, d-amphetamine, primarily by red blood cells after oral administration.(2) The pharmacokinetics of LDX has been described in detail in a recent review.”
BackgroundWeisler, R., Young, J., Mattingly, G., Gao, J., Squires, L., Adler, L., & 304 Study Group (2009) · CNS Spectrums · doi:10.1017/s1092852900024056 · Cited by 94 · cited 7×
“Anxiety and palpitations were also reported by more than 2% of study participants in the short-term studies.1,4 The increases from baseline in SBP and pulse observed in this study are also consistent with observations from the short-term studies of LDX1,4; DBPwas increased in this study and in the pivotal phase 3 stud…”
BackgroundResultInfluentialFindling, R. L., Childress, A. C., Krishnan, S., & McGough, J. J. (2008) · CNS Spectrums · doi:10.1017/s1092852900016898 · Cited by 90
Findling, R. L., Cutler, A. J., Saylor, K., Gasior, M., Hamdani, M., Ferreira-Cornwell, M. C., & Childress, A. C. (2013) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2011.0088 · Cited by 40
Self-citationLisdexamfetamine: A pharmacokinetic review
Comiran, E., Kessler, F. H., Fröehlich, P. E., & Limberger, R. P. (2016) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2016.04.026 · Cited by 31
Cited by
Giel, K. E., Bulik, C. M., Fernandez-Aranda, F., Hay, P., Keski-Rahkonen, A., Schag, K., Schmidt, U., & Zipfel, S. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00344-y · Cited by 296
Psychopharmacological advances in eating disorders
Himmerich, H., & Treasure, J. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1383895 · Cited by 119
Ward, K., & Citrome, L. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1420163 · Cited by 32
“This pattern continued in a safety and tolerability study that was 1 year in duration [57].”
BackgroundMethodInfluentialAmodeo, G., Cuomo, A., Bolognesi, S., Goracci, A., Trusso, M. A., Piccinni, A., Neal, S. M., Baldini, I., Federico, E., Taddeucci, C., et al. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1571041 · Cited by 25
Q da Luz, F., Hay, P., Wisniewski, L., Cordás, T., & Sainsbury, A. (2021) · Obesity Reviews · doi:10.1111/obr.13180 · Cited by 20
Metadata
- Authors
- Gasior, M., Hudson, J., Quintero, J., Ferreira-Cornwell, M. C., Radewonuk, J., & McElroy, S. L.
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2017-06
- Volume
- 37
- Issue
- 3
- Pages
- 315-322
- ISSN
- 0271-0749 (ISSN-L)
- 1533-712X
- OpenAlex
- W2605218699
- Cited by
- 60
- References
- 8
- FWCI
- 6.95
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Phase 3, Multicenter, Open-Label, 12-Month Extension Safety and Tolerability Trial of Lisdexamfetamine Dimesylate in Adults With Binge Eating Disorder. https://app.cochat.ai/papers/10.1097/jcp.0000000000000702
- The paper
- Gasior, M., Hudson, J., Quintero, J., Ferreira-Cornwell, M. C., Radewonuk, J., & McElroy, S. L. (2017). A Phase 3, Multicenter, Open-Label, 12-Month Extension Safety and Tolerability Trial of Lisdexamfetamine Dimesylate in Adults With Binge Eating Disorder. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/jcp.0000000000000702
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.